Finoriq research workspace
20/20 Biolabs, Inc. (AIDX) Institutional Holdings & 13F Ownership
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for. Review AIDX institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
- Company
- 20/20 Biolabs, Inc. (AIDX)
- Ticker
- AIDX
- Market Cap
- $6.4M
- Latest Price
- $0.5188
- Industry
- Precision Instruments
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.